# Nixxy, Inc.: financial statements, quarterly

NIXX · Nasdaq · CIK 1462223 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/nixx.md) · [Financials](/companies/nixx/financials.md) · [Filings](/companies/nixx/filings.md) · [Insiders](/companies/nixx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/nixx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.2](/filings/0001654954-24-014482.md) | [0.2 d](/filings/0001654954-25-003709.md) | [0.2](/filings/0001683168-25-003886.md) | [0.1](/filings/0001683168-25-006041.md) | [0.1](/filings/0001683168-25-008338.md) | [(0.5) d](/filings/0001683168-26-002951.md) | [1.3](/filings/0001683168-26-003816.md) | [13.4](/filings/0001683168-26-006274.md) | [31.9](/filings/0001683168-25-008338.md) | [51.1 d](/filings/0001683168-26-002951.md) | [29.1](/filings/0001683168-26-003816.md) | [16.1](/filings/0001683168-26-006274.md) |
| Cost of revenue | $m | [0.3](/filings/0001654954-24-014482.md) | [0.6 d](/filings/0001654954-25-003709.md) | [0.0](/filings/0001654954-24-006538.md) | [0.0](/filings/0001654954-24-010646.md) | [0.0](/filings/0001654954-24-014482.md) | [(0.0) d](/filings/0001654954-25-003709.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $m | [(0.1)](/filings/0001654954-24-014482.md) | [(0.4) d](/filings/0001654954-24-010638.md) | [0.2](/filings/0001654954-24-006538.md) | [0.1](/filings/0001654954-24-010646.md) | [0.1](/filings/0001654954-24-014482.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [0.1](/filings/0001654954-24-014482.md) | [0.0 d](/filings/0001654954-25-003709.md) | [0.0](/filings/0001683168-25-003886.md) | [0.0](/filings/0001683168-25-006041.md) | [0.0](/filings/0001683168-25-008338.md) | [0.0 d](/filings/0001683168-26-002951.md) | [0.0](/filings/0001683168-26-003816.md) | [0.0](/filings/0001683168-26-006274.md) | [0.2](/filings/0001683168-25-008338.md) | [0.0 d](/filings/0001683168-26-002951.md) | [0.0](/filings/0001683168-26-003816.md) | [0.0](/filings/0001683168-26-006274.md) |
| Selling, general and administrative | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [(2.1)](/filings/0001654954-24-014482.md) | [(1.6) d](/filings/0001654954-25-003709.md) | [(1.1)](/filings/0001683168-25-003886.md) | [(1.0)](/filings/0001683168-25-006041.md) | [(5.5)](/filings/0001683168-25-008338.md) | [(5.5) d](/filings/0001683168-26-002951.md) | [(3.8)](/filings/0001683168-26-003816.md) | [(2.2)](/filings/0001683168-26-006274.md) | [(2.2)](/filings/0001683168-25-008338.md) | [(2.1) d](/filings/0001683168-26-002951.md) | [(1.2)](/filings/0001683168-26-003816.md) | [(1.6)](/filings/0001683168-26-006274.md) |
| Interest expense | $m | [0.6](/filings/0001654954-24-014482.md) | [(1.8) d](/filings/0001654954-25-003709.md) | [0.4](/filings/0001654954-24-006538.md) | [0.2](/filings/0001654954-24-010646.md) | [0.1](/filings/0001654954-24-014482.md) | [(0.6) d](/filings/0001654954-25-003709.md) | [0.0](/filings/0001683168-26-003816.md) | [0.0](/filings/0001683168-26-006274.md) | [0.0](/filings/0001683168-25-008338.md) | [0.0 d](/filings/0001683168-26-002951.md) | [0.0](/filings/0001683168-26-003816.md) | [0.0](/filings/0001683168-26-006274.md) |
| Income tax | $m | [0.0](/filings/0001654954-24-014482.md) | [0.0 d](/filings/0001654954-25-003709.md) | [0.0](/filings/0001683168-25-003886.md) | [0.0](/filings/0001683168-25-006041.md) | [0.0](/filings/0001683168-25-008338.md) | [0.0 d](/filings/0001683168-26-002951.md) | [0.0](/filings/0001683168-26-003816.md) | [0.0](/filings/0001683168-26-006274.md) | [0.0](/filings/0001683168-25-008338.md) | [0.0 d](/filings/0001683168-26-002951.md) | [0.0](/filings/0001683168-26-003816.md) | [0.0](/filings/0001683168-26-006274.md) |
| Net income | $m | [(1.0)](/filings/0001654954-24-014482.md) | [(1.8) d](/filings/0001654954-25-003709.md) | [(0.8)](/filings/0001654954-24-010646.md) | [(1.0)](/filings/0001683168-25-006041.md) | [(13.3)](/filings/0001683168-25-008338.md) | [(7.5) d](/filings/0001683168-26-002951.md) | [(4.5)](/filings/0001683168-26-006274.md) | [(4.3)](/filings/0001683168-26-006274.md) | [(2.2)](/filings/0001683168-25-008338.md) | [(4.1) d](/filings/0001683168-26-002951.md) | [0.5](/filings/0001683168-26-006274.md) | [(2.3)](/filings/0001683168-26-006274.md) |
| Diluted EPS | $ per share | not reported | not reported | [(0.40)](/filings/0001683168-25-003886.md) | [(0.35)](/filings/0001683168-25-006041.md) | [(2.66)](/filings/0001683168-25-008338.md) | not reported | [(0.29)](/filings/0001683168-26-003816.md) | [(0.22)](/filings/0001683168-26-006274.md) | [(0.10)](/filings/0001683168-25-008338.md) | not reported | [0.02](/filings/0001683168-26-003816.md) | [(0.08)](/filings/0001683168-26-006274.md) |
| Basic EPS | $ per share | not reported | not reported | [(0.40)](/filings/0001683168-25-003886.md) | [(0.35)](/filings/0001683168-25-006041.md) | [(2.66)](/filings/0001683168-25-008338.md) | not reported | [(0.29)](/filings/0001683168-26-003816.md) | [(0.22)](/filings/0001683168-26-006274.md) | [(0.10)](/filings/0001683168-25-008338.md) | not reported | [0.02](/filings/0001683168-26-003816.md) | [(0.08)](/filings/0001683168-26-006274.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | period not labelled (2024-02-13) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [1.0](/filings/0001654954-24-010646.md) | not reported | [0.3](/filings/0001654954-24-006538.md) | [0.3](/filings/0001654954-24-010646.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current assets | $m | [2.0](/filings/0001654954-25-003709.md) | not reported | [0.9](/filings/0001654954-24-006538.md) | [0.8](/filings/0001654954-24-010646.md) | [2.6](/filings/0001654954-24-014482.md) | [3.2](/filings/0001683168-26-002951.md) | [1.8](/filings/0001683168-25-003886.md) | [1.6](/filings/0001683168-25-006041.md) | [1.3](/filings/0001683168-25-008338.md) | [2.0](/filings/0001683168-26-006274.md) | [5.1](/filings/0001683168-26-003816.md) | [5.3](/filings/0001683168-26-006274.md) |
| Total assets | $m | [10.5](/filings/0001654954-25-003709.md) | not reported | [10.1](/filings/0001654954-24-006538.md) | [9.8](/filings/0001654954-24-010646.md) | [11.2](/filings/0001654954-24-014482.md) | [7.0](/filings/0001683168-26-002951.md) | [11.8](/filings/0001683168-25-003886.md) | [13.3](/filings/0001683168-25-006041.md) | [16.1](/filings/0001683168-25-008338.md) | [13.2](/filings/0001683168-26-006274.md) | [15.6](/filings/0001683168-26-003816.md) | [15.1](/filings/0001683168-26-006274.md) |
| Current liabilities | $m | [9.6](/filings/0001654954-25-003709.md) | not reported | [7.1](/filings/0001654954-24-006538.md) | [7.2](/filings/0001654954-24-010646.md) | [4.4](/filings/0001654954-24-014482.md) | [4.4](/filings/0001683168-26-002951.md) | [6.2](/filings/0001683168-25-003886.md) | [6.5](/filings/0001683168-25-006041.md) | [5.5](/filings/0001683168-25-008338.md) | [5.2](/filings/0001683168-26-006274.md) | [5.5](/filings/0001683168-26-003816.md) | [6.8](/filings/0001683168-26-006274.md) |
| Total liabilities | $m | [9.6](/filings/0001654954-25-003709.md) | not reported | [7.1](/filings/0001654954-24-006538.md) | [7.2](/filings/0001654954-24-010646.md) | [4.4](/filings/0001654954-24-014482.md) | [4.4](/filings/0001683168-26-002951.md) | [6.2](/filings/0001683168-25-003886.md) | [6.5](/filings/0001683168-25-006041.md) | [5.5](/filings/0001683168-25-008338.md) | [5.2](/filings/0001683168-26-006274.md) | [5.5](/filings/0001683168-26-003816.md) | [6.8](/filings/0001683168-26-006274.md) |
| Long-term debt | $m | not reported | [0.5](/filings/0001654954-25-003709.md) | not reported | not reported | not reported | [1.2](/filings/0001683168-26-002951.md) | [1.2](/filings/0001683168-25-003886.md) | [1.2](/filings/0001683168-25-006041.md) | [0.0](/filings/0001683168-25-008338.md) | [0.0](/filings/0001683168-26-002951.md) | not reported | not reported |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [0.9](/filings/0001654954-25-003709.md) | not reported | [3.0](/filings/0001654954-24-014482.md) | [2.6](/filings/0001654954-24-014482.md) | [6.8](/filings/0001654954-24-014482.md) | [2.6](/filings/0001683168-26-002951.md) | [5.4](/filings/0001683168-25-003886.md) | [6.6](/filings/0001683168-25-006041.md) | [10.4](/filings/0001683168-25-008338.md) | [8.0](/filings/0001683168-26-006274.md) | [10.1](/filings/0001683168-26-003816.md) | [8.3](/filings/0001683168-26-006274.md) |

- Cash and equivalents: us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(160) d](/filings/0001654954-24-014482.md) | [925 d](/filings/0001654954-25-003709.md) | [(670)](/filings/0001683168-25-003886.md) | [(555) d](/filings/0001683168-25-006041.md) | [(483) d](/filings/0001683168-25-008338.md) | [(2,389) d](/filings/0001683168-26-002951.md) | [(1,839)](/filings/0001683168-26-003816.md) | [(1,191) d](/filings/0001683168-26-006274.md) | [(1,021) d](/filings/0001683168-25-008338.md) | [(516) d](/filings/0001683168-26-002951.md) | [(385)](/filings/0001683168-26-003816.md) | [(982) d](/filings/0001683168-26-006274.md) |
| Capital expenditure | $k | not reported | [0.0 d](/filings/0001654954-24-010638.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Dividends paid | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $k | not reported | [0.0 d](/filings/0001654954-24-010638.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: not reported
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q2 FY2020 (2020-06-30) | Q3 FY2020 (2020-09-30) | Q2 FY2021 (2021-06-30) | Q3 FY2021 (2021-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [1.9](/filings/0001654954-21-008966.md) | [8.8](/filings/0001654954-21-012202.md) | [5.9](/filings/0001654954-22-011368.md) | [13.6](/filings/0001654954-21-012202.md) | [1.9](/filings/0001683168-25-003886.md) | [2.9](/filings/0001683168-25-006041.md) | [5.0](/filings/0001683168-25-008338.md) | [15.4](/filings/0001683168-26-003816.md) | [19.1](/filings/0001683168-26-006274.md) | [21.6](/filings/0001683168-25-008338.md) | [26.2](/filings/0001683168-26-003816.md) | [28.0](/filings/0001683168-26-006274.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 28,908,839 at 2026-08-13, from the cover of the [10-Q filed 2026-08-12](/filings/0001683168-26-006274.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:40 ET. No prices; not investment advice.